Study details
Enrolling now
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
University of Alabama at Birmingham
NCT IDNCT05183048ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
14
Study length
about 5 years
Ages
18+
Locations
1 site in AL
What this study is about
Researchers are testing if Zirconium-89 (89Zr) panitumumab imaging can better identify the size and location of head and neck squamous cell carcinoma tumors compared to standard Fludeoxyglucose (18F-FDG) imaging in newly diagnosed patients undergoing surgery. The trial is for imaging purposes only and will not change your treatment plan.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [89Zr]Panitumumab Tracer
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
injection (Injection)
Body systems
Oncology